Get started
Author

Thomas Cummin

Observed names: Cummin, Thomas Edward Comyn, T. Cummin, T. E. C. Cummin, T.E. Cummin, Thomas E C Cummin, Thomas E Cummin, Thomas E. C. Cummin, Thomas E. Cummin
ORCID: 0000-0001-8251-0300
Observed ORCIDs: 0000-0001-8251-0300, 0000-0003-3152-6315
OpenAlex ID: A5113857809
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy
2018 · Chulin Sha, Sharon Barrans, et al. · Journal of Clinical Oncology · 302
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
2019 · Andrew Davies, Thomas E Cummin, et al. · The Lancet Oncology · 274
PDF
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit
2019 · Francesco Cucco, Sharon Barrans, et al. · Leukemia · 118
PDF
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expression
2020 · Thomas E. C. Cummin, Kerry L. Cox, et al. · Blood Advances · 42
PDF
Management of secondary central nervous system lymphoma
2022 · Kate Cwynarski, Thomas Cummin, et al. · British Journal of Haematology · 26
DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBL): a PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMODL‐B
2017 · A.J. Davies, S. Barrans, et al. · Hematological Oncology · 17
PDF
Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality
2018 · Francesco Cucco, Alexandra Clipson, et al. · Laboratory Investigation · 14
PDF
Lymphoma: turning biology into cures
2016 · Thomas Cummin, Peter Johnson · Clinical Medicine · 8
PDF
Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
2020 · Andrew Davies, Josh Caddy, et al. · Blood · 6
Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study
2022 · Andrew J Davies, Josh Caddy, et al. · Blood · 4
Accept: a Phase Ib/ii Combination of Acalabrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (r‐chop) for Patients With Diffuse Large B‐cell Lymphoma (dlbcl)
2019 · T.E. Cummin, J. Caddy, et al. · Hematological Oncology · 4
Prognostic Significance and Correlation to Gene Expression Profile of Ezh2 Mutations in Diffuse Large B ‐cell Lymphoma ( Dlbl ) in 2 Large Prospective Studies
2017 · T.E. Cummin, S. Araf, et al. · Hematological Oncology · 4
PDF
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
2022 · Findlay Bewicke-Copley, Koorosh Korfi, et al. · Blood Advances · 3
PDF
Induction Chemo-Immunotherapy with the Matrix Regimen in Patients with Newly Diagnosed PCNSL - a Multicenter Retrospective Analysis on Feasibility and Effectiveness in Routine Clinical Practice
2017 · Elisabeth Schorb, Chris P Fox, et al. · Blood · 3
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes
2026 · Laura Li Gagnon, Andrea Duminuco, et al. · Leukemia · 2
PDF
87 | THE PRiZM+ PHASE II PLATFORM STUDY FOR RELAPSED AND REFRACTORY PRIMARY CNS LYMPHOMA: FIRST RESULTS FROM COHORT 1 ZANUBRUTINIB MONOTHERAPY
2025 · C. P. Fox, J. Wang, et al. · Hematological Oncology · 2
PDF
Longitudinal Analyses of Diagnostic‐relapse Biopsies of Diffuse Large B Cell Lymphoma Suggest That Relapse Is Mediated by Distinct Mechanisms in Abc and Gcb Lymphoma
2019 · K. Korfi, S. Araf, et al. · Hematological Oncology · 2
Targeted Therapeutics for Lymphoma: Using Biology to Inform Treatment
2018 · T. E. C. Cummin, M. S. Cragg, et al. · Mechanical engineering series · 2
Argo: a Randomised Phase Ii Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B‐cell Lymphoma Who Are Not Candidates for High‐dose Therapy
2019 · A.J. Davies, O. Tansley Hancock, et al. · Hematological Oncology · 1
Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone as First-Line Therapy for Patients With Diffuse Large B-Cell Lymphoma
2026 · Andrew J. Davies, Louise Stanton, et al. · JCO oncology advances.
PDF
Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel
2019 · Findlay Bewicke-Copley, Koorosh Korfi, et al. · Blood
High Expression of Bcl‐2 and Bcl‐xl in Diffuse Large B‐cell Lymphoma Confer Poor Prognosis but May Be Reversible by Combined Inhibition With Bet Inhibitors and Bh3 Mimetics.
2019 · T.E. Cummin, K. Cox, et al. · Hematological Oncology
PDF
Precision medicine for patients with lymphoma; the Bloodwise Precision Medicine for Aggressive Lymphomas (PMAL) consortium
2019 · Bridgin Merron, Shamim Kazmi-Stokes, et al. · Clinical Medicine
Longitudinal Analyses of the Genomic, Transcriptomic, and T Cell Repertoire in Diffuse Large B Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse
2017 · Shamzah Araf, Koorosh Korfi, et al. · Blood
DIffuse large B-cell lymphoma
2016 · Thomas Cummin · ePrints Soton (University of Southampton)
Works count: 26
Citation count: 834
H-index: 8
I10-index: 7
Year
Topic
Type